1. Introduction {#s0005}
===============

Immunological assays for the detection of antinuclear antibodies (ANA) are useful and important complementary tools for the diagnosis and follow-up of patients with autoimmune diseases [@bib1]. The identification of the antigen--antibody coupling is the common end-point for all techniques; however, several differences exist as for the utility, sensitivity, specificity, and predictive values of each test [@bib1], [@bib2].

In general, if a patient presents clinical manifestations of an autoimmune disease, the first test to be requested is ANA detection by indirect immunofluorescence using HEp-2 cells, due to its great sensitivity [@bib1], [@bib3]. The different possible patterns, the intensity, and the titers obtained by consecutive dilutions must be carefully examined. Identification of the antigens recognized by the ANA is further evaluated by more specific tests such as ELISA, radioimmunoanalysis (RIA) or electroimmunotransference (EIT) [@bib2], [@bib4].

The use of these tests requires knowledge of their fundamental aspects and also of the clinical classification criteria of each disorder in order to contribute to an appropriate diagnosis [@bib5], [@bib6].

The usefulness of this testing has been evaluated in retrospective studies of patients with systemic rheumatic disease (SRD), and it has been proven that its positive predictive value is low due to the relatively large amount of false positive results. For specific rheumatic diseases, the ANA test yields a positive predictive value of 11%, a negative predictive value of 97%, and a sensitivity and specificity of 42% and 85% respectively [@bib7].

Several physiological and pathological factors might favor the development of ANA in the non-rheumatic population, such as pregnancy, advanced age, family history of autoimmune disease, as well as infectious, cardiovascular or oncological diseases [@bib8], [@bib9], [@bib10], [@bib11], [@bib12]. This situation conveys challenges such as interpretative standardization [@bib13].

A high percentage of patients with high autoantibodies titers do not manifest any clinical signs of autoimmune disease. This may be due to the existence of circulating antigens that are not routinely tested for, such as those resulting from infectious stimuli, from multifactorial synthesis or those naturally produced by CD5+ cells [@bib14]. For this reason, clinicians should pay close attention to the titers in which the ANAs are reported, taking into account that in healthy individuals, antibodies should be negative or can be present in low titers, and that intermediate titers may be present in non-affected relatives of patients with autoimmune diseases or in elders with chronic infections or neoplasms [@bib8], [@bib11], [@bib12], [@bib15].

In Mexico, ANA prevalence has been studied in healthy individuals and consensus has been reached as to consider positive a gross mottled pattern in dilutions over 1:160, while homogeneous, centromeric, peripheral or centriolar patterns should be considered positive even in dilutions as low as 1:40 [@bib16]. Their presence can be, nevertheless, due to natural antigens [@bib14], [@bib17], [@bib18].

In some instances the recognition of antibodies directed to known antigens cannot be achieved. This complicates the accurate measurement of the antibody's predictive value [@bib19], [@bib20].

The objective of the present study was to determine the predictive values (PPV, NPV) of ANA testing for suspected SDR by analyzing the pre-test assessment of rheumatologic clinical criteria as well as post-test diagnosis.

2. Methods {#s0010}
==========

We analyzed samples for ANA studies requested to our lab during a twelve-month period. The tests were selected if they were performed by IIF in HEp-2 cells (INOVA Diagnostics INC San Diego USA) and if an initial positive result at a 1:40 dilution led to successive dilutions. An informed consent was obtained for each test form each patient.

Furthermore, the presence of specific auto-antibodies was evaluated by ELISA (ORGENTEC Diagnostica GmBh Carl-Seiss Mainz,Germany) using purified extractable nuclear antigens (ENA) for Sm, RNP/Sm, SSA/Ro, SSB/LA, Anti-Scl-70, and anti-centromere as well as crithidia luciliae substrate.

An ANA test was considered to be positive when titers were superior to the following dilutions: Nuclear pattern: homogeneous\>1:40, coarse speckled and fine speckled\>1:160, laminar and peripheral\>1:40. Cell cycle: nucleolar, centromeric, and centriolar\>1:40. Cytoplasmic\>1:80 and micotocondrial\>1:160.

Each patient\'s clinical file was reviewed by a qualified rheumatologist to acknowledge, if the suspected diagnosis was confirmed or if there was an alternative final diagnosis. We confirmed form the records the evaluation made for the presence of diagnostic clinical criteria in each patient. Clinical criteria considered for each disease the following the guidelines for diagnosis.

2.1. Statistical analysis {#s0015}
-------------------------

Sample size was calculated by correlation as follows:$$n = \frac{n\prime}{1 + n\prime \cdot N}$$$$n\prime = \frac{S^{2}}{\sigma^{2}}$$

where *N*=1374, standard error, Se=0.025, *p*=0.18, *S*^2^ the sample variance *p*(1−*p*)=(018)(1−*p*)=(0.18) (0.82)=0.1476}, *σ*^2^ is the population variance, (Se)^2^ (0.025)^2^=0.000625.$$n\prime\frac{S^{2}}{\sigma^{2}} = \frac{0.1476}{0.000625} = 236$$$$n\frac{n\prime}{1 + n\prime/Ν} = \frac{236}{1 + 236/1374} = \frac{236}{1 + 0.17176} = \frac{236}{1.17176} = 201.5 = 202$$**Sample size**=**202.**

We included a total of 373 samples for this study, tendency measures with mean and standard deviation were obtained for variables with parametric distribution. Non-parametric variables were analyzed with percentages, median and ranges. Statistical analysis was performed using Spearman's correlation, Chi-square and exact Fisher's test with SPSS version 16 and Epi-info version 6.

3. Results {#s0020}
==========

A total of 373 requests for ANA evaluation were received. 299 (80%) corresponded to women and 74 (20%) to men. Mean age was 40±15 and 37±17 years, respectively.

In 364 (83%) samples, nuclear antibodies were found with dilutions 1:40 and no antibodies were found in 9 cases (2%). In 193 out of the 364 (52%) antibodies against specific antigens were found.

Frequency of test requests and use of clinical criteria by each department from our institution are shown in [Table 1](#t0005){ref-type="table"}.

There was a total of 373 ANA tests performed. In 364 (98%) patients, antibodies were found in dilutions of 1:40. Out of these, SRD was confirmed in 213 (57%) cases and it could not be confirmed in 160 (42%).

From the 213 patients with confirmed SRD, in 187 (88%) clinical criteria were applied prior to the blood test, but only in 167 (78%) SRD was confirmed. In 20 patients (9%), the clinical criteria were applied but no autoimmune disease could be diagnosed. 120 individuals (56%) were diagnosed with SRD by both clinical and laboratory criteria. In 47 cases (22%), clinical criteria were used prior to requesting the ANA test but no antigen-specific antibodies were found; 22 (10%) patients had no clinical criteria applied prior to requesting the test, but ANAs could be found in high dilutions and were positive against specific antigens. Therefore the physician concluded that the patients had an autoimmune disease. Finally, there were 24 patients (11%) with no clinical criteria applied prior to soliciting the ANA test and no antigen-specific antibodies were found, however, they presented IIF patterns compatible with autoimmune disease on in high titers.

No autoimmune disease was found in 160 patients. In 6 (4%) of them, clinical criteria were applied prior to soliciting the ANA test, but antibodies were found only in dilutions of 1:40 with antigen-specific antibodies, and in 49 patients (31%) no clinical criteria were applied and the antibodies were found only in low ANA titers and antigen-specific antibodies. Also, from these 160 patients, 91 (57%) had not previously met the mentioned clinical criteria according to the suspected SRD.

These also corresponded mainly to patients with heart or kidney disease.

Dilutions that predominated were 1:40 although there was some percentage of antibodies in high titers. Even an antigen-specific antibody could be found in 8 cases; in these, the attending physicians applied their clinical judgment and discarded SRD. Regardless if they presented specificity towards an antigen or not, when the criteria were applied SRD was demonstrated in 167 patients (78%) while SRD could only be diagnosed in 46 (22%) when no criteria were used.

No SRD was found in 141 (88%) of the requests for ANA test in which no clinical criteria were applied compared to 19 (12%) in the group in which clinical criteria were used. This difference achieved statistical significance with an OR of 26 (95% CI 14--50, *p*\<0.0001). This analysis strongly supports the application of clinical criteria prior to the request of antibody testing in patients in whom autoimmune disease is suspected.

The pretest probability of the antigen-specific antibody test is of 57%. Whenever clinical criteria are applied, we observed an improvement of 32%. Nevertheless, when the antibody test was used to confirm SRD without the use of clinical criteria this value diminished to 15% as shown in [Table 2](#t0010){ref-type="table"}.

Further analysis of the information revealed that when clinical criteria and specific antibodies are present, we achieve a sensitivity of 57% and a specificity of 96%; when one or both are negative we get an increase in sensitivity but a loss in specificity. We evaluated the effect of various combinations of these results in [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}

The aforementioned improvement in the post-test likelihood ratio results should be observed every time considering both tools (clinical criteria and specific antinuclear antibody testing) are not independent for the diagnosis of autoimmune disease but usually sequential.

Pre-test probability is 0.57$$\frac{0.57}{1 - 0.57} = 1.3$$The likelihood ratio for stand-alone testing and their combined utility is shown in [Table 5](#t0025){ref-type="table"}, in panel A we see the that pre-test likelihood for a patient with suspected autoimmune disease when a test for antigen-specific antibodies is requested is 1.94; the post-test probability with an antigen-specific antibody can be calculated as follows:$$\frac{1.94}{1.94 + 1} = 65\%\quad{Probabilitypost}-{test}$$Calculating the post-test likelihood ratio when clinical criteria were used to classify the disease we obtain a result of 3.55 (Panel B) and a post-test probability of 78%.$$\frac{3.55}{3.55 + 1} = 78\%\quad{Probabilitypost}-{test}$$Panel C shows the result from combining both assessments against the application of only one evaluation (clinical or serological).

As presented in [Table 6](#t0030){ref-type="table"}, Panel A (patients with autoimmune disease were=213), sensitivity was 72% when clinical criteria were used prior to antigen-specific antibodies (T-tasa FP) while it only was 48% when they were not applied and antibody testing was performed directly.

Both tests are independent (in Panel B) (patients without autoimmune disease=160), the specificity for not having autoimmune disease was of 65% when the clinical criteria were negative or not used. However, when the test was negative and clinical criteria had been used, the specificity of ANA was 70% in this series. In patients in whom antigen-specific antibodies are found, the probability to diagnose them by clinical classification criteria is high while patients with a negative antibody test have a higher probability of not presenting any clinical manifestations. This supposed concordance should be further evaluated in larger series.

As shown in [Table 7](#t0035){ref-type="table"} panel a, the likelihood ratio to find an autoimmune disease is of 14.97 when both clinical criteria and the ANA test for specific antigens yield positive results; a repeated ANA test would not significantly increase the likelihood ratio.

As shown in [Table 7](#t0035){ref-type="table"} panel b, clinical criteria as a stand-alone tool (LR+=6.24) and the study of ANA against specific antigens (LR+=2.4) when positive results in a high LR of 6.24×2.4=14.97; likewise, the likelihood ratio when both tests are positive, starting form ANA against specific antigens as a stand-alone tool (LR+=1.94) and clinical criteria (LR+=7.72) when positive results in a similar LR, 1.94×7.72=14.97. Therefore, the decision to request an antigen-specific antibody test can become more complex.

In this study we also described the frequency of ANA, specificity for specific antigens, and type of nuclear pattern and their relationship with SRD. These results are shown in [Table 8](#t0040){ref-type="table"}.

Equally rare patterns such as pattern NuMA antibodies were found in 7 cases (2%), out of which 5 were women and 3 men, with a mean age of 33 (28--64) for women and 52 (21--57) for men. Two of them were diagnosed with secondary APS, one with SLE plus AS, another one with SLE plus limited systemic sclerosis, one with rheumatoid arthritis and Sjogren\'s syndrome, one with ANCA-associated vasculitis and pulmonary thromboembolism, and a last one with atrial tachycardia plus pulmonary arterial hypertension.

Two females presented PCNA antibodies; one was diagnosed with Takayasu arteritis and the other one with SLE plus dilated myocardiopathy. Two cases were reported as having antibodies against proliferating cells.

In non-rheumatic diseases we found anti-DNA antibodies, 3% in patients with cardiopathy, 33% in those with hypothyroidism and 13% in nephropathies not associated with SLE. Predictive values of the tests in relationship with clinical phenotype of SRD are shown in [Table 9](#t0045){ref-type="table"}.

The frequency of different patterns of antibodies documented in this sample were: discrete speckled (DS) 179 (48%), DS- centromere 8 (2%), DS-NuMA 3 (0.8%), DS-Na, DS-Jo, DS-mitochondrial, DS-nucleolar (N) and DS-homogeneous patterns were present in 0.3% each. Homogeneous pattern (H) in 109 (29%), both H and N in 3 (0.8%), H-speckled in 1 (0.3%); Coarse speckled in (CS) 17 (5%), CS-NuMA 4 (1%), speckled 2 (0.5%), cytoplasm 1 (0.3%). Homogeneous, DS and CS patterns were all observed in high titers ([Fig. 1](#f0005){ref-type="fig"}).

Thirty-five (22%) patients without autoimmune disease presented ANA in 1:40 dilutions, but none were observed in dilutions over 1:320.

In cases with SRD, ANA could be found in dilutions over 1:320 in 199 (57%) compared to those without autoimmune disease 44 (26%), OR 3.45 (CI 95%, 2.19--5.50), and in dilutions between 1:2560 and 5120 71 (39%) in SLE, scleroderma, mixed connective tissue disease, overlap, Sjogren's syndrome and rheumatoid arthritis plus systemic lupus erythematous. Even though they were observed in non-autoimmune diseases, this percentage was lower: 12 (8%), OR 5.88 (CI 95%, 2.95--11.94) ([Fig. 1](#f0005){ref-type="fig"}a--h).

4. Discussion {#s0025}
=============

It is known that positive and negative predictive values for any test are dependent upon the disease\'s prevalence, with false positive results increasing in those samples in which the disease has a low prevalence, therefore decreasing the test\'s positive predictive value [@bib7].

Healthy subject, people with non-autoimmune diseases and those with a family history of autoimmune disease present a high percentage of antibodies in low titers [@bib21], [@bib22].

Our series reveals that the predictive value of the test is low, and that it is lower if proper clinical criteria are not applied when requesting the test [@bib21]. Positive antibodies in low titers may lead to confusion when trying to establish a diagnosis, and can become problematic when they are found at higher titers.

It is well known that any test such as antibodies against a specific antigen conveys false positive and false negative results. This can lead to diagnostic and therapeutic errors by utilizing measures when they are not required [@bib23], [@bib24].

In this analysis, we see that using clinical criteria before requesting the test provides a considerable improvement in the diagnostic workup. Antibodies considered to be specific for SLE, such as double strand anti-DNA, have been reported as well in Sjogren\'s syndrome, dermatomyositis and cutaneous sclerosis [@bib25], [@bib26], [@bib27], [@bib28], [@bib29]. In our series the percentage of SLE patients with positive ANA was of 49%, with varying frequency ranges from 6% to 50%,when SLE coexisted with other diseases, and in 90% of patients with renal damage, a finding known to bear a worse prognosis [@bib30], [@bib31], [@bib32], [@bib33]. In non-rheumatic diseases we found anti-DNA antibodies in frequencies similar to those previously reported in the literature, supporting the idea of the existence of an immunological alteration in cardiovascular and renal diseases, which might be explained by previous infections [@bib15], [@bib34], [@bib35].

Antibodies directed towards ribonucleoproteins (SM, RNP, SSB) are usually detected in SLE, but not in discoid lupus. Our results concur with previous literature [@bib31], [@bib36]. As for SM antibodies, there are reported presence of them in 15--40% of cases; we found that they are present in 30% of cases of SLE when not associated with other diseases, with ranges that vary from 15% to 50% when another SRD coexists with SLE or there is damage to a specific organ [@bib37], [@bib38]. Quite remarkable, elevated ANA titers are important in the diagnostic of rheumatic diseases, but it is also very important to be familiar to each laboratory\'s cut-off points. Also the type of pattern of antibodies was found in some cases in close correlation with the presence of some autoimmune diseases. It is known that antibodies directed against ribonucleoproteins are associated with connective tissue diseases [@bib39]. An homogeneous pattern might be proof of reaction against native single or double stranded DNA and associated with SLE. The centromeric pattern is characteristic of CREST syndrome and those against nucleolar RNA are associated with SLE and systemic progressive sclerosis [@bib40]. However, other unusual nuclear ANAs are those against the Nuclear mitotic apparatus (NuMA), which might or might not be reported accurately depending upon the laboratory\'s experience [@bib41]. Their positivity is associated with connective tissue disease, 45% corresponding to Sjogren's syndrome and undifferentiated connective tissue disease as well as autoimmune diseases against specific organs in 17% even though up to 38% have been found in non-autoimmune diseases [@bib42].

In this study 2% of patients had NuMA, and they were associated with primary AS, one of them with optic neuritis and a possible Devic syndrome. The prevalence of these antibodies and their clinical significance has been previously reported in the literature [@bib43], [@bib44].

Antibodies against the nuclear antigen of proliferative cells were described over 30 years ago in patients with chronic hepatitis B or C, and they have only been found in about 5% of patients with SLE. Their clinical significance has been recently studied in a metanalysis and they have also been detected in polymyositis, systemic sclerosis and even healthy individuals. However their prevalence has not surpassed 2% in any group [@bib45]. In this study, they were detected in two cases, one of them a 64-year-old woman with SLE and end stage renal disease, and the second one in a 23-year-old female with Takayasu arteritis and systemic arterial hypertension.

The presence of specific antibodies against cellular components such as nuclear or cytoplasmic molecules are specific for some diseases [@bib46], [@bib47] while some other might be completely nonspecific [@bib48], [@bib49]. Moreover other findings might depend upon a clinical characteristic of the disease, such as neuropsychiatric lupus in which anti-p ribosomal antibodies have a 10% prevalence and were observed in 2% of all patients with SLE [@bib46]. Nevertheless, some antibodies are related with organ specific alterations and could be prognostic markers [@bib50]. Commonly, when a non-rheumatologist specialist requests an ANA test in a patient it is due to the presence of inflammatory signs and symptoms that most physicians would not overlook. However antibody-testing results does not consider previous clinical details and specific diagnosis becomes quite difficult [@bib51], [@bib52], [@bib53], [@bib54].

We were able to confirm the dispersion and utility that these results have depending upon the clinicians' specialty, the use of clinical criteria, and indirectly, the knowledge of some recommendations from guidelines.

We believe that in some cases the severity of the clinical picture and diagnostic uncertainty may justify requesting for these tests, however a positive result might turn out to be a confusing factor and therefore require an interpretation that should into account, in first place, the clinical context.

The use of the test in patients with SRD and a positive result might lead to a second test. Several studies attempting to obtain an appropriate use of laboratory tests have been published with the fair purpose of reducing unnecessary testing [@bib4], [@bib55], [@bib56].

A non-medical factor, knowledge of the techniques and standardized procedures, contributes to the optimal use of the test. Other variables could contribute to the variability of the results such as ethnicity, the use of clinical criteria, and the coexistence of several autoimmune diseases or presence of several other antigens.

On the other hand, when the prevalence of a disease in a sample is low, positive predictive value tends to be low as well dictating the need to confirm the result by using a second test.

We found a low prevalence of autoimmune diseases in the requests of these tests, which were solicited by several specialists with differing criteria.

From another view, the high percentage of false positives may be attributed to the fact that only a certain set of antibodies are routinely tested for, not including other recognized antibodies such as antihistone, antinucleosomes, CENP-B, CENP-A, CENP-C, Sp100 protein, PML or NDP53, which could increase the predictive value of the test [@bib57], [@bib58], [@bib59], [@bib60], [@bib61], [@bib62].

Specificity can be increased when clinical criteria and diagnostic algorithms are applied. This reduces unnecessary ANA tests and correlating with a better analysis, utilization, and clinical judgment by the physicians [@bib52], [@bib63], [@bib64].

5. Conclusion {#s0030}
=============

Positive and negative predictive value for the ANA test is low, it is dependent on the clinical context of the patient and if the physician relies on clinical criteria for its request. The use of clinical criteria specific for each probable disease prior to antinuclear antibodies testing increases the likelihood ratio for the diagnosis of autoimmune diseases. This also depends upon the phenotype of the disease and the coexistence of two or more diseases or the presence of other antigens, which are not routinely tested for in all laboratories.

The proper use of laboratory tests, in accordance to knowledge and interdisciplinary communication, significantly improves the diagnostic yield of specialized evaluations.

![Microphotographs of indirect immunofluorescence of specific antibodies in Hep2 cells. (a) Cytoplasmic P-ribosomal pattern. (b) NuMA-1 pattern. (c) Centromeric or discrete speckled pattern. (d) SSA discrete speckled pattern. (e) Homogeneous pattern. (f) Nucleolar with mitochondrial pattern.](gr1){#f0005}

###### 

Percentage of positive ANA requested by several medical specialties and correlation with the use of clinical classification criteria.

  Department             Total of tests requested (%)   Used clinical criteria   Antibodies in 1:40 dilution   Did not use clinical criteria   With specific antigen   With confirmed AD 213   With autoimmune disease (AD) 213   Without AD 160   Without autoimmune disease 160                                                                       
  ---------------------- ------------------------------ ------------------------ ----------------------------- ------------------------------- ----------------------- ----------------------- ---------------------------------- ---------------- -------------------------------- ------------- -------------- ----------- ------------ ------------- -------------
  Rheumatology           278 (75)                       170 (61)                 274                           108 (39)                        156                     194/278 (70)            111 (57)                           44 (23)          18 (9)                           21 (11)       84 (30)        4 (5)       11 (13)      25 (30)       44 (52)
  Immunology             6 (2)                          3 (50)                   34                            3 (50)                          3                       5 /6 (83)               2 (40)                             1 (20)           1 (20)                           1 (20)        1 (17)         0           0            0             1 (100)
  Nephrology             34 (9)                         9 (27)                   18                            25 (73)                         17                      11/34 (33)              7 (67)                             1 (9)            2 (18)                           1 (9)         23 (68)        0           1 (4)        7 (30)        15 (65)
  Adult cardiology       27 (7)                         4 (15)                   26                            23 (85)                         8                       1/27 (4)                0 (0)                              0                1 (100)                          0             26 (96)        2 (8)       2 (8)        7 (27)        15 (58)
  Cardiopneumology       20 (5)                         1 (5)                    3                             19 (95)                         3                       2/20 (5)                0                                  1 (1)            0                                1 (50)        18 (90)        0           0            4 (22)        14 (77)
  Emergency department   3 (0.8)                        0 (0)                    4                             3 (100)                         3                       0 (0)                   0 (0)                              0                0                                0             3 (100)        0           0            3 (100)       0
  Pediatric cardiology   5 (1)                          0 (0)                    5                             5 (100)                         3                       0 (0)                   0 (0)                              0                0                                0             5 (100)        0           0            3 (60)        2 (40)
  Total                  373 (100)                      187 (50)                 364                           186 (50)                        193                     213/373 (57)            120/213 (56)                       47/213 (22)      22/213 (10)                      24/213 (11)   160/373 (43)   6/160 (4)   14/160 (8)   49/160 (31)   91/160 (57)

AD: autoimmune disease,UCCBR: utilized clinical criteria before the request of test, NUCBR: non-utilized clinical criteria before request of test, Sp(+): positive antibody specificity Sp(−): negative antibody specificity.

###### 

Systemic rheumatic disease probability prior to test antibodies.

  Antibodies to specific antigen                With autoimmune disease   Without Autoimmune disease         Pretest probability (specific antigen)    Change of the probability after the test (%)
  --------------------------------------------- ------------------------- ---------------------------- ----- ----------------------------------------- ----------------------------------------------
  \+                                            142                       55                           197   142/197=72% (PPV)                         **15**
  −                                             71                        105                          176   105/176=60% (NPV)                         **3**
  Total                                         213                       160                          373                                             
                                                *S*=(142/213)=67%         *E*=(105)/(160)=66%                                                          
                                                                                                                                                       
  Solicitors utilization of clinical criteria   With autoimmune disease   Without autoimmune disease         Pretest probability (clinical criteria)   Change of the probability after the test (%)
                                                                                                                                                       
  \+                                            167                       20                           187   167/187=89%                               **32**
  −                                             46                        140                          186   140/186=75%                               **18**
  Total                                         213                       160                          373                                             
                                                *S*=167/213=78%           *E*=140/160=88%                                                              
                                                                                                                                                       

The application of clinical criteria appropriate to request the test is 213/373=57%.

*S*=sensibility, *E*=specificity.

###### 

Complex tables to evaluate both tools for diagnosis of autoimmune diseases (appropriate clinical criteria and specific auto-antibodies).

  Clinical criteria and specific antibodies   With autoimmune disease   Without autoimmune disease   
  ------------------------------------------- ------------------------- ---------------------------- -----
  Both positive                               120                       6                            127
  One positive                                69                        63                           130
  Both negative                               24                        91                           116
  Total                                       213                       160                          373
                                                                                                     

  Effect of locating the cut-off point at different levels                       
  ---------------------------------------------------------- --------- --------- ---------
  120                                                        6         189       69
  93                                                         154       24        91
  213                                                        160       213       160
  *S*=57%                                                    *E*=96%   *S*=89%   *E*=57%

*S*=sensitivity, *E*=specificity.

###### 

Complex tables to evaluate both tools for diagnosis of autoimmune diseases (appropriate clinical criteria and specific auto-antibodies).

  Cut-off point between one and two positive tests              With autoimmune disease   Without autoimmune disease         Likelihood of autoimmune disease after the test
  ------------------------------------------------------------- ------------------------- ---------------------------- ----- -------------------------------------------------
  Both positive test (clinical criteria+ specific antibodies)   120                       6                            127   120/127=94%
  One or both negative                                          93                        154                          246   93/246=38%
  Total                                                         213                       160                          373   
                                                                                                                             

  Cut-off point between one and two negative tests          With autoimmune disease   Without autoimmune disease         Cut-off point between one and both tests negative
  --------------------------------------------------------- ------------------------- ---------------------------- ----- ---------------------------------------------------
  One or both positives                                     189                       69                           258   189/258=73%
  Both clinical criteria and specific antibodies negative   24                        91                           115   24/115=21%
  Total                                                     213                       160                          373   

###### 

Likelihood ratio for each test.

  **(a) Specific-antigen antibodies**                                                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------- ------------------------- ---------------------------- ------------------ -------------- ------------------
  \+                                                                                                                         142                       142/213=0.66                 55                 55/(160=0.34   0.66/(0.34=1.94
  −                                                                                                                          71                        71/230=0.30                  105                105/160=0.65   0.30/0.65=0.46
  Total                                                                                                                      213                                                    160                               
                                                                                                                                                                                                                      
  **(b) Clinical criteria**                                                                                                                                                                                           
  Classification according to criteria                                                                                       With autoimmune disease   Without autoimmune disease   Likelihood ratio                  
  Number                                                                                                                     Proportion                Number                       Proportion                        
                                                                                                                                                                                                                      
  \+                                                                                                                         167                       167/213=0.78                 20                 20/160=0.34    0.78/0.22=3.55
  −                                                                                                                          46                        46/213=0.22                  140                140/160=0.88   0.30/0.65=0.39
  Total                                                                                                                      213                                                    160                               
                                                                                                                                                                                                                      
  **(c) Effect of different combinations of specific antibodies and clinical criteria over the diagnostic workup for SRD**                                                                                            
                                                                                                                             Number                    Proportion                   Number             Proportion     Likelihood ratio
                                                                                                                                                                                                                      
  Clinical criteria and specific antibodies positive                                                                         120                       120/213=0.56                 6                  6/160=0.037    0.56/0.037=15.02
  One or both negative                                                                                                       93                        93/213=0.44                  154                154/160=0.96   0.44/0.96=0.45
  Total                                                                                                                      213                                                    160                               

###### 

Evaluation of the combination of positive results on specific antibodies and utilization of clinical criteria for the diagnosis of autoimmune disease.

  **Panel A: Patients with autoimmune disease**                                                                                                                                                
  ----------------------------------------------- -------------------------------------------------------------------- ----------- ------------- ------------------------------- ------------- -------------
  With clinical criteria                          120                                                                  47          167           With clinical criteria (+)      120/167=72%   
  Without clinical criteria                       22                                                                   24          46            Without clinical criteria (−)   22/46=48%     
  Total                                           142                                                                  71          213           160                                           142/213=67%
                                                                                                                                                                                               
                                                  Sensitivity of specific antigen antibodies (1-true positive ratio)                                                                           
  When specific antibodies (+)                    When specific antibodies (−)                                         Total                                                                   
                                                                                                                                                                                               
                                                  120/142=85%                                                          47/71=66%   167/213=78%                                                 
                                                                                                                                                                                               

  **Panel B: Without autoimmune disease**                                                                                                                                                
  ----------------------------------------- -------------------------------------------------------------------- ------------ ------------- ------------------------------- ------------ -------------
  With clinical criteria                    6                                                                    14           20            With clinical criteria (+)      14/20=70%    
  Without clinical criteria                 49                                                                   91           140           Without clinical criteria (−)   91/140=65%   
  Total                                     55                                                                   105          160           160                                          105/160=65%
                                                                                                                                                                                         
                                            Sensitivity of specific antigen antibodies (1-true positive ratio)                                                                           
  When specific antibodies (+)              When specific antibodies (−)                                         total                                                                   
                                                                                                                                                                                         
                                            49/55=89%                                                            91/105=87%   140/160=87%                                                

###### 

\(a\) Likehood ratios when two converging tools for autoimmune disease are positive. (b) Likelihood ratios for SRD diagnosis.

  \(a\)                                                                                                                 
  ------------------------------------------------------------ ----------------------------------- -------------------- ------------------
  Both positive tool (clinical criteria CC and specific ANA)   120 (56%)                           6 (3.7%)             0.56/0.038=14.97
  0.44/0.96=0.46                                                                                                        
  One or both                                                  47                                  14                   
  +22                                                          +49                                                      
  +24                                                          +91                                                      
  --                                                           --                                                       
  93 (44%)                                                     154 (96%)                                                
  Total                                                        213 (100%)                          160 (100%            
                                                                                                                        
  \(b\)                                                                                                                 
                                                               Positive Likelihood Ratio (L.R.+)                        
  Clinical criteria                                            AAN against specific antigen                             
                                                                                                                        
  Stand-alone test                                             1−(0.78/(1−0.87))=6.24              0.66/(1−0.66)=1.94   
  When the other test was positive                             (0.85/(1−0.89))=7.72                0.72/(1−0.70)=2.4    

###### 

Frequency of nuclear patterns and antibodies against specific antigens in several autoimmune diseases.

  Disease                Antigen   Pattern                                                                                        
  ---------------------- --------- --------- --------- --------- -------- -------- -------- --------- --------- -------- -------- -------
  SLE                    43        13 (31)   13 (30)   13 (30)   4 (9)    1 (2)    1(2)     24 (56)   13 (27)   0        0        1 (2)
  RA+SLE                 8         2 (10)    3 (38)    4(50)     2 (25)   0        0        5 (63)    6 (75)    0        0        0
  SLE+APS                13        1 (5)     2 (15)    4 (30)    0        0        0        4 (31)    6 (43)    0        1 (8)    0
  SLE+SS                 3         0         1 (33)    2 (67)    2 (67)   0        0        1 (33)    2 (67)    0        0        0
  Discoid lupus          6         0         1 (17)    0         0        0        1        2 (33)    2 (33)    0        0        0
  SLE+hyperthyroidism    2         0         1(50)     0         0        0        0        1 (50)    3 (50)    0        0        0
  SLE+hypothyroidism     5         0         0         3 (60)    1 (20)   0        0        2 (50)    0         0        0        0
  RA                     17        0         0         1 (6)     0        0        0        10 (59)   2 (12)    0        0        0
  RA+SS                  10        1 (10)    1 (10)    5 (50)    4 (40)            0        3 (30)    5 (50)    0        1 (10)   0
  RA+hypothyroidism      1         0         0         0         0        0        0        1 (100)   0         0        0        0
  IJA                    5         0         0         0         0        0        0        3 (60)    2 (40)    0        0        0
  Scleroderma            16        2 (10)    5 (31)    3(18)     0        1 (6)    3 (19)   1 (6)     7 (44)    0        1 (6)    0
  SCL+SS                 2         0         0         1 (50)    1 (50)   0        1 (50)   0         1 (50)    0        0        0
  SCL                    2         0         0         0         0        1 (50)   1(50)    1 (50)    1 (50)    0        0        0
  MCTD                   5         0         4 (90)    2 (40)    0        1 (14)   0        0         5 (100)   0        0        0
  Overlap                8         1 (5)     2 (25)    2 (25)    0        1 (15)   1(15)    3 (38)    0         0        0        0
  Polymyositis           2         0         0         1 (50)    0        0        1 (50)   0         0         1        0        0
  Dermatomyositis        1         0         0         0         0        0        0        0         1 (100)   0        0        0
  SS                     8         0         0         0         5 (62)   0        0        2 (25)    5 (63)    0        0        0
  SS+hypothyroidism      2         0         0         0         0        0        0        0         1 (50)    0        0        0
  Devic syndrome         3         0         0         1 (33)    0        0        0        0         2 (67)    0        0        0
  PAPS                   38        0         0         2(5)      0        0        1        9 (24)    22 (58)   2 (5)    2 (5)    0
  Fibromyalgia           7         0         1(3)      0         0        0        1        1 (14)    4 (57)    0        0        0
  Cardiopathy            94        1         5         1         1        0        0        18 (19)   58 (62)   6 (6)    2 (2)    0
  Hypothyroidismo        3         0         0         1(3)      0        0        0        2 (67)    1 (33)    0        0        0
  Nephropathy            24        0         0         0         0        0        0        3 (13)    9 (38)    4 (17)   0        0
  Cancer                 2         0         0         0         0        0        0        0         1 (50)    0        0        0
  Takayasu's arteritis   1         0         0         0         0        0        0        0         0         0        0        1

APS=antiphospholipid syndrome, IJA=idiopathic juvenile arthritis, MCTD=mixed connective tissue disease, PAPS=primary antiphospholipid syndrome, RA=rheumatoid arthritis, SCL=scleroderma, SLE=systemic erythematous lupus, SS=systemic scleroderma.

###### 

Sensibility, specificity, and predictive values according to autoimmunity disease and specificity of antibodfies.

                       SM       DNA      SSA      SSB      RNP
  -------------------- -------- -------- -------- -------- --------
  SLE                  *S*=35   *S*=62   *S*=40   *S*=25   *S*=43
  *N*=37               *E*=99   *E*=99   *E*=96   *E*=99   *E*=87
                       PPV=93   PPV=96   PPV=70   PPV=91   PPV=71
                       NPV=86   NPV=88   NPV=86   NPV=84   NPV=87
                                                           
  RA+SLE               *S*=25   *S*=50   *S*=50   *S*=25   *S*=38
  *N*=8                *E*=99   *E*=99   *E*=94   *E*=99   *E*=96
                       PPV=67   PPV=80   PPV=31   PPV=67   PPV=30
                       NPV=96   NPV=97   NPV=97   NPV=96   NPV=97
                                                           
  Discoid lupus        *S*=0    *S*=20   *S*=0    *S*=0    *S*=25
  *N*=6                *E*=94   *E*=99   *E*=94   *E*=99   *E*=96
                       PPV=0    PPV=50   PPV=0    PPV=0    PPV=13
                       NPV=98   NPV=97   NPV=96   NPV=97   NPV=98
                                                           
  SLE+APS              *S*=10   *S*=17   *S*=33   *S*=0    S=15
  *N*=11               *E*=99   *E*=99   *E*=94   *E*=93   *E*=96
                       PPV=50   PPV=67   PPV=30   PPV=0    PPV=22
                       NPV=94   NPV=94   NPV=95   NPV=93   NPV=93
                                                           
  SLE+SS               *S*=33   *S*=33   *S*=67   *S*=67   S=33
  *N*=3                *E*=99   *E*=99   *E*=94   *E*=99   *E*=96
                       PPV=50   PPV=50   PPV=18   PPV=67   PPV=14
                       NPV=99   NPV=99   NPV=99   NPV=99   NPV=99
                                                           
  SLE+hypothyroidism   *S*=0    *S*=25   *S*=75   S=33     *S*=0
  *N*=4                *E*=99   *E*=99   *E*=94   *E*=99   *E*=96
                       PPV=0    PPV=50   PPV=25   PPV=50   PPV=0
                       NPV=97   NPV=98   NPV=79   NPV=99   NPV=98
                                                           
  Sjogren's syndrome   *S*=0    *S*=0    *S*=0    *S*=38   *S*=0
  *N*=8                *E*=99   *E*=99   *E*=94   *E*=97   *E*=96
                       PPV=0    PPV=0    PPV=0    PPV=75   PPV=0
                       NPV=99   NPV=96   NPV=99   NPV=97   NPV=95
                                                           
  PAPS                 *S*=0    *S*=15   *S*=5    *S*=0    *S*=0
  *N*=35               *E*=99   *E*=99   *E*=82   *E*=82   *E*=95
                       PPV=0    PPV=80   PPV=18   PPV=0    PPV=0
                       NPV=80   NPV=85   NPV=82   NPV=82   NPV=82
                                                           
  RA                   *S*=0    *S*=20   *S*=13   *S*=0    *S*=0
  *N*=16               *E*=99   *E*=99   *E*=94   *E*=99   *E*=95
                       PPV=0    PPV=50   PPV=18   PPV=0    PPV=0
                       NPV=99   NPV=97   NPV=92   NPV=91   NPV=91
                                                           
  IJA                  *S*=0    *S*=20   *S*=0    *S*=0    *S*=0
  *N*=5                *E*=99   *E*=99   *E*=94   *E*=99   *E*=95
                       PPV=0    PPV=50   PPV=0    PPV=0    PPV=0
                       NPV=99   NPV=97   NPV=99   NPV=97   NPV=91
                                                           
  Scleroderma          *S*=67   *S*=13   *S*=23   *S*=0    *S*=38
  *N*=12               *E*=99   *E*=99   *E*=95   *E*=99   *E*=96
                       PPV=67   PPV=50   PPV=22   PPV=0    PPV=41
                       NPV=93   NPV=95   NPV=94   NPV=99   NPV=95
                                                           
  Crest                *S*=0    *S*=0    *S*=0    *S*=0    *S*=60
  *N*=5                *E*=99   *E*=99   *E*=99   *E*=99   *E*=96
                       PPV=0    PPV=0    PPV=0    PPV=0    PPV=30
                       NPV=80   NPV=99   NPV=99   NPV=99   NPV=99

APS=antiphospholipid syndrome, IJA=Idiopathic juvenile arthitis, MCTD=mixed connective tissue disease, PAPS=primary antiphospholipid syndrome, RA=rheumatoid arthritis, SCL=scleroderma, SLE=systemic lupus erythematosus, SS=systemic scleroderma, *S*=sensitivity, *E*=specificity, PPV=positive predictive value, NPV=negative predictive value.
